Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nuvalent, Inc. - Class A Common Stock (NQ: NUVL ) 82.06 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nuvalent, Inc. - Class A Common Stock < Previous 1 2 3 Next > From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update October 28, 2024 The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). Via News Direct Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? September 22, 2024 Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. Via Benzinga Topics Economy Exposures Interest Rates Why Nuvalent (NUVL) Shares Are Down 6% Today September 17, 2024 Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each. Via Benzinga Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity September 16, 2024 Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in... Via Benzinga Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths September 16, 2024 Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test. Via Investor's Business Daily Topics Death Exposures Death NUVL Stock Earnings: Nuvalent Misses EPS for Q2 2024 August 08, 2024 NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 May 09, 2024 NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Crude Oil Surges Over 1%; Instil Bio Shares Plunge September 16, 2024 Via Benzinga Exposures Fossil Fuels Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday September 16, 2024 Via Benzinga Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio? August 25, 2024 Via Benzinga 3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally June 24, 2024 Although short-squeeze stocks to buy present great risk, betting against the bears can also yield dramatically robust returns. Via InvestorPlace Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? June 09, 2024 Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. Via Benzinga Recap: Nuvalent Q4 Earnings February 27, 2024 Via Benzinga Recap: Nuvalent Q3 Earnings November 14, 2023 Via Benzinga 7 Biotech Stocks to Get In Now Before Investors Catch On October 23, 2023 Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. Via InvestorPlace Why Nuvalent Stock Tanked on Tuesday October 17, 2023 The dilution monster stalked the company following the announcement of a new capital-raising effort. Via The Motley Fool Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet October 06, 2023 Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... Via Benzinga Why Nuvalent Stock Skyrocketed 35% This Week October 05, 2023 Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know. Via The Motley Fool Where Nuvalent Stands With Analysts October 05, 2023 Via Benzinga Why Nuvalent Stock Was Soaring Wednesday October 04, 2023 The company reported preliminary data on a non-small cell lung cancer therapy. Via The Motley Fool Expert Ratings for Nuvalent August 08, 2023 Via Benzinga Nuvalent: Q1 Earnings Insights May 11, 2023 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session October 04, 2023 Via Benzinga Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold September 27, 2023 Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients,... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 September 27, 2023 Via Benzinga Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session September 18, 2023 Gainers Via Benzinga Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday September 18, 2023 U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. Via Benzinga 7 A-Rated Biotech Stocks for Your August Buy List August 17, 2023 Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 August 08, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 July 24, 2023 Via Benzinga < Previous 1 2 3 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
